Maze Therapeutics (NASDAQ:MAZE) Trading 8.7% Higher – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price was up 8.7% on Friday . The stock traded as high as $28.35 and last traded at $29.3630. Approximately 808,898 shares were traded during mid-day trading, an increase of 17% from the average session volume of 692,634 shares. The stock had previously closed at $27.02.

Wall Street Analysts Forecast Growth

MAZE has been the topic of several analyst reports. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. HC Wainwright raised their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday. Finally, BTIG Research restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Stock Up 5.2%

The stock’s fifty day simple moving average is $25.68 and its 200-day simple moving average is $35.98. The stock has a market cap of $1.57 billion, a P/E ratio of -11.24 and a beta of 2.26. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $266,461.11. The trade was a 41.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $381,689.60. The trade was a 16.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 102,360 shares of company stock worth $2,722,140 in the last quarter. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MAZE. Janus Henderson Group PLC grew its stake in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after buying an additional 362,060 shares in the last quarter. Woodline Partners LP raised its position in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after buying an additional 94,529 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Maze Therapeutics by 9.0% during the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after acquiring an additional 69,771 shares during the period. Finally, ArrowMark Colorado Holdings LLC boosted its position in shares of Maze Therapeutics by 40.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock worth $31,793,000 after acquiring an additional 222,251 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.